MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.17
-0.33
-2.44%
Opening 15:13 01/27 EST
OPEN
13.00
PREV CLOSE
13.50
HIGH
13.51
LOW
12.84
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
14.89
52 WEEK LOW
3.870
MARKET CAP
1.27B
P/E (TTM)
-5.9752
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TGTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TGTX News

  • TG Therapeutics Option Alert: Feb 21 $19 Calls Sweep (2) above Ask!: 2189 @ $0.276 vs 3922 OI; Earnings 2/28 Before Open [est] Ref=$13.43
  • Benzinga.4d ago
  • TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Increased Their Holdings
  • Simply Wall St..6d ago
  • H.C. Wainwright Maintains Buy on TG Therapeutics, Raises Price Target to $24
  • Benzinga.01/17 13:59
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07

More

Industry

Biotechnology & Medical Research
-0.72%
Pharmaceuticals & Medical Research
-0.34%

Hot Stocks

Name
Price
%Change

About TGTX

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
More

Webull offers TG Therapeutics Inc (TGTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.